AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs.
Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 - MAS, Adult onset Still's Disease, Chronic Obstructive Pulmonary Disease and many others.
AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases.
Extensive Phase I and Ib clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in NLRC4 – MAS and in Adult onset Still’s Disease.
March 21, 2019 - AB2 Bio announces readiness for recruitment in pivotal Phase 3 trial of Tadekinig alfa, a novel human recombinant interleukin-18 binding protein, in children with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency, with amended design in the U.S. and Canada